Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06567002 · ClinicalTrials.gov registry record · Phase 1
A Study of MK-6552 and the Effect of Food in Healthy Participants (MK-6552-006)
A Phase 1 study, sponsored by Merck Sharp & Dohme.
- Terminated
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT06567002 is a Phase 1 study that was terminated before completion, run by Merck Sharp & Dohme. The registered enrollment target is 24 participants.
The verdict
NCT06567002, a Phase 1 study, was terminated before completion, sponsored by Merck Sharp & Dohme.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
The primary purpose of this study is to learn what happens to levels of MK-6552 in the blood when MK-6552 is given in different forms to healthy adult participants under fasted and fed conditions.
Interventions
- DRUG MK-6552
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2024-09-09 |
| Est. Completion | 2024-11-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06567002
The ClinicalTrials.gov registry entry for NCT06567002 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which MK-6552 is the first listed.
NCT06567002 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06567002 about?
NCT06567002 is a clinical study titled "A Study of MK-6552 and the Effect of Food in Healthy Participants (MK-6552-006)". The primary purpose of this study is to learn what happens to levels of MK-6552 in the blood when MK-6552 is given in different forms to healthy adult participants under fasted and fed conditions.
What is the current status of trial NCT06567002?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2024-09-09. Estimated completion is 2024-11-15.
What interventions are being tested in trial NCT06567002?
The interventions under investigation include: MK-6552 (DRUG).
Who is sponsoring clinical trial NCT06567002?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.